6Y4 Stock Chart & Stats
€0.92
€0.08(9.48%)
At close: 4:00 PM EST
€0.92
€0.08(9.48%)
Day’s Range― - ―
52-Week Range€0.64 - €1.86
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€325.90M
Enterprise Value€2.27B
Total Cash (Recent Filing)€1.06B
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Aug 21, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding281,525,600
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.47
Price to Sales (P/S)710.16
P/FCF Ratio-7.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.21Price Target Upside248.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.15
Revenue Forecast (FY)€79.86K
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetThe company reports essentially zero debt and materially expanded equity, providing durable financial flexibility. Low leverage reduces refinancing risk and supports funding of clinical programs without interest burdens, allowing management to prioritize R&D spending and strategic options over the medium term.
Focused Clinical-stage Pipeline (AT2R / IPF)A clear strategic focus on AT2R-targeted therapies for idiopathic pulmonary fibrosis and severe lung diseases creates a durable specialization. This concentrated pipeline can yield differentiated clinical data and long-term value if outcomes succeed, and positions the company in a high-unmet-need therapeutic niche.
Capital-light Clinical Development ModelAs a clinical-stage developer, the company avoids the large fixed costs of commercial manufacturing and sales operations. This structural model keeps overhead lower and focuses capital deployment on trials and development activities, which is sustainable if managed amid funding constraints.
Bears Say
Severe And Persistent Cash BurnConsistent and worsening negative operating cash flow implies ongoing reliance on external financing. Over a multi-quarter horizon this raises dilution and execution risk for clinical programs, constrains strategic optionality, and makes long-term program continuity dependent on successful capital raises or partnerships.
Volatile And Collapsing RevenueA sharp, recent revenue decline undermines predictability of resources available for development. Volatility suggests revenue may be event-driven or nonrecurring, reducing visibility on sustainable funding and increasing the probability that management must divert focus to stopgap financing instead of long-term R&D priorities.
Deep, Widening Operating LossesVery large operating and net losses relative to revenue indicate high cash burn and poor near-term returns on capital. Persistent negative margins and negative ROE imply continued equity dilution or partnership dependency to fund programs, elevating execution and shareholder-value risk over the medium term.
Vicore Pharma Holding AB News
6Y4 FAQ
What was Vicore Pharma Holding AB’s price range in the past 12 months?
Vicore Pharma Holding AB lowest stock price was €0.64 and its highest was €1.86 in the past 12 months.
What is Vicore Pharma Holding AB’s market cap?
Vicore Pharma Holding AB’s market cap is €325.90M.
When is Vicore Pharma Holding AB’s upcoming earnings report date?
Vicore Pharma Holding AB’s upcoming earnings report date is Aug 21, 2026 which is in 41 days.
How were Vicore Pharma Holding AB’s earnings last quarter?
Vicore Pharma Holding AB released its earnings results on May 06, 2026. The company reported -€0.036 earnings per share for the quarter, beating the consensus estimate of -€0.044 by €0.008.
Is Vicore Pharma Holding AB overvalued?
According to Wall Street analysts Vicore Pharma Holding AB’s price is currently Undervalued.
Does Vicore Pharma Holding AB pay dividends?
Vicore Pharma Holding AB does not currently pay dividends.
What is Vicore Pharma Holding AB’s EPS estimate?
Vicore Pharma Holding AB’s EPS estimate is -0.04.
How many shares outstanding does Vicore Pharma Holding AB have?
Vicore Pharma Holding AB has 281,525,600 shares outstanding.
What happened to Vicore Pharma Holding AB’s price movement after its last earnings report?
Vicore Pharma Holding AB reported an EPS of -€0.036 in its last earnings report, beating expectations of -€0.044. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vicore Pharma Holding AB?
Currently, no hedge funds are holding shares in DE:6Y4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vicore Pharma Holding AB
Vicore Pharma Holding AB (publ), a Gothenburg, Sweden-based company, specializes in the discovery and advancement of therapies for rare lung conditions. Its core pipeline features VP01, an orally administered small molecule currently in Phase II clinical trials for indications such as interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19. The company is also progressing VP02, a novel formulation and delivery approach for an established immunomodulatory compound, which is in preclinical development for treating IPF. Vicore maintains strategic alliances, including a development cooperation with Emeriti Bio AB, a licensing arrangement with Nanologica AB (publ), and a collaboration with Alex Therapeutics AB focused on creating and clinically validating a digital therapeutic (DTx) built on the Alex DTx platform. Established in 2000, the company was formerly known as Mintage Scientific AB.
6Y4 Stock 12 Month Forecast
Average Price Target
€3.21
▲(248.66% Upside)
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
SynAct Pharma AB
―
Xspray Pharma AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---